Alexey Manikhas

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Luca Gianni, W. Eiermann, Alexey Manikhas et al. · The Lancet · 2010 · 1.3K citations

Medicine, Oncology, Breast Oncology +16

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

Stephen Johnston, John Pippen, Xavier Pivot et al. · Journal of Clinical Oncology · 2009 · 1K citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

José Baselga, Peter van Dam, Alexey Manikhas et al. · Journal of Clinical Oncology · 2009 · 658 citations

Medicine, Oncology, Pharmacology +17

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

J.F.R. Robertson, Ekaterina Trishkina, Mikhail Dvorkin et al. · The Lancet · 2016 · 602 citations · Full text

Medicine, Oncology, Pharmacology +14

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Xavier Pivot, Alexey Manikhas, Zurawski Bogdan et al. · Journal of Clinical Oncology · 2015 · 251 citations · Full text

Medicine, Oncology, Pharmacology +17